In 60 heart failure patients with implanted sensors, semaglutide or tirzepatide tracked with lower pressures and yearly hospitalizations falling from 1.2 to 0.3, researchers report.
Recap by typeshit. Full story at HCPLive.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
A new review in Cureus pulls together efficacy and safety evidence on orforglipron, the daily pill alternative to injectable GLP-1 drugs.
Clinical trials point to GLP-1 drugs possibly helping with alcohol, opioid and nicotine addiction by changing how the brain responds, per U.S. News.
Loading…